Skip to main navigation Skip to search Skip to main content

iPLEDGE weaknesses: Is it time to address the flaws?

  • Amanda A. Cyrulnik
  • , Aron J. Gewirtzman
  • , Karin Blecher Paz
  • , Jaimie B. Glick
  • , Anika K. Anam
  • , Daniel A. Carrasco
  • , Alan R. Shalita
  • , Steven R. Cohen

Research output: Contribution to journalArticlepeer-review

Abstract

BACKGROUND: The observance during acne follow-ups that information stored within iPLEDGE was discordant with medical charts prompted this study. OBJECTIVE: To evaluate the information acquired and stored within iPLEDGE as it compares to medical charts with a goal of assessing the efficacy of iPLEDGE as a database. METHODS: This is a multicenter retrospective chart review analyzing congruence and discrepancies between medical chart documentation and iPLEDGE data for all patients who received at least a single dose of isotretinoin from the primary investigators between January 2006 and November 2010. RESULTS: A total of 357 charts were analyzed. Overall congruence between medical chart documentation and iPLEDGE data was observed in only 73.1% of cases. The discrepancy (N=96) was due to a missed dose (prescription recorded in chart but not in iPLEDGE) in 81.4% of cases, or an addition (medication dispensed per iPLEDGE without corresponding chart documentation) in the remainder of cases. Of note, several charts had multiple discrepancies (N=249 total discrepancies). LIMITATIONS: Retrospective chart review study. CONCLUSION: Given the large percentage of discordant data, our findings question the efficacy of the iPLEDGE system, which is designed to monitor every dispensed isotretinoin dose.

Original languageEnglish (US)
Pages (from-to)97-102
Number of pages6
JournalJournal of Drugs in Dermatology
Volume15
Issue number1
StatePublished - Jan 2016

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'iPLEDGE weaknesses: Is it time to address the flaws?'. Together they form a unique fingerprint.

Cite this